ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring MET exon 14 skipping alterations (METex14)
第一作者单位:[1]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
推荐引用方式(GB/T 7714):
Yu Yongfeng,Ren Yongxin,Fang Jian,et al.ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring MET exon 14 skipping alterations (METex14)[J].CANCER RESEARCH.2021,81(13):
APA:
Yu, Yongfeng,Ren, Yongxin,Fang, Jian,Cao, Lejie,Liang, Zongan...&Lu, Shun.(2021).ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring MET exon 14 skipping alterations (METex14).CANCER RESEARCH,81,(13)
MLA:
Yu, Yongfeng,et al."ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring MET exon 14 skipping alterations (METex14)".CANCER RESEARCH 81..13(2021)